{"id":485494,"date":"2021-05-03T06:48:19","date_gmt":"2021-05-03T10:48:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/"},"modified":"2021-05-03T06:48:19","modified_gmt":"2021-05-03T10:48:19","slug":"reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/","title":{"rendered":"Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">PLANO, Texas, May  03, 2021  (GLOBE NEWSWIRE) &#8212; Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (\u201cReata,\u201d the \u201cCompany,\u201d or \u201cwe\u201d), a clinical-stage biopharmaceutical company, today announced that management will present and hold 1&#215;1 meetings at the following investor conferences:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Bank of America Merrill Lynch Global Healthcare Conference on May 12, 2021.<\/li>\n<li style=\"text-align:justify\">Jefferies Virtual Healthcare Conference on June 2, 2021.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About Reata Pharmaceuticals, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata\u2019s two most advanced clinical candidates, bardoxolone methyl (&#8220;bardoxolone&#8221;) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling.\u00a0<strong>Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.<\/strong><\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"left\">\n        <em>This press release includes certain disclosures that contain \u201cforward-looking statements,\u201d including, without limitation, statements regarding the success, cost, and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, our plans to submit regulatory filings, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as \u201cbelieves,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201caims,\u201d \u201cplans,\u201d \u201cmodel,\u201d and \u201cexpects.\u201d Forward-looking statements are based on Reata\u2019s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) whether regulatory authorities determine that additional trials or data are necessary in order to obtain approval; (iv) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (v) other factors set forth in Reata\u2019s filings with the U.S. Securities and Exchange Commission, including the detailed factors discussed under the caption \u201cRisk Factors\u201d in its Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.<\/em>\n      <\/p>\n<p align=\"left\">\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Reata Pharmaceuticals, Inc.<br \/>(972) 865-2219<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T51VATbPe6CWD2o5czhPk4IFI3HGiYHAU_YgTU_6FHkQ1XuAtacfl5OtlIsjR5PVMX15xSjtUrDDPbi6BGqEoLnhA5FKvAPNjxfBRsPp_x4=\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/reatapharma.com\/<\/a><\/p>\n<p align=\"left\">\n        <strong>Investor Relations &amp; Media:<\/strong><br \/>\n        <br \/>Manmeet Soni<br \/>Andres Lorente<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ezLULvE9EjpmbHnymMZzt7uCI9iIfR5tlzajqtuBAXh84z7AH-_MFSQj3bpeJEW0Zu6wVKmivFJO3ho9rdsULJHv7gkzJYD8mNsgp3mDvCM=\" rel=\"nofollow noopener\" target=\"_blank\">ir@reatapharma.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hh0RrZUXx_c49EY_jkevezD6dewkrnEcFYGTfuWHSzQHcA8gdIyE-1KO_bibU_nZ99t6H7XA9QcJ7WPz6c9FOYHKliPyK7MpfTMXgiZcHSo=\" rel=\"nofollow noopener\" target=\"_blank\">media@reatapharma.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T51VATbPe6CWD2o5czhPk4IFI3HGiYHAU_YgTU_6FHmfcamkrbli72FuCWtPVCMIR36AymW5DN262HseZVZWLNQI0CzOd_SpDMswD7GoIKQCOHVo5pnx2XnQZQB83oLWyWQkZHomdiFOtrVWAncI5BWJaH6KsDlkM28y8RmZrEU=\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/reatapharma.com\/contact-us\/<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNzY0OCM0MTU5NzAzIzIwMjAyNDM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/2e2da099-451a-4fe0-8efc-6c2b43332f28\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PLANO, Texas, May 03, 2021 (GLOBE NEWSWIRE) &#8212; Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (\u201cReata,\u201d the \u201cCompany,\u201d or \u201cwe\u201d), a clinical-stage biopharmaceutical company, today announced that management will present and hold 1&#215;1 meetings at the following investor conferences: Bank of America Merrill Lynch Global Healthcare Conference on May 12, 2021. Jefferies Virtual Healthcare Conference on June 2, 2021. About Reata Pharmaceuticals, Inc. Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata\u2019s two most advanced clinical candidates, bardoxolone methyl (&#8220;bardoxolone&#8221;) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-485494","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PLANO, Texas, May 03, 2021 (GLOBE NEWSWIRE) &#8212; Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (\u201cReata,\u201d the \u201cCompany,\u201d or \u201cwe\u201d), a clinical-stage biopharmaceutical company, today announced that management will present and hold 1&#215;1 meetings at the following investor conferences: Bank of America Merrill Lynch Global Healthcare Conference on May 12, 2021. Jefferies Virtual Healthcare Conference on June 2, 2021. About Reata Pharmaceuticals, Inc. Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata\u2019s two most advanced clinical candidates, bardoxolone methyl (&#8220;bardoxolone&#8221;) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative &hellip; Continue reading &quot;Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-03T10:48:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNzY0OCM0MTU5NzAzIzIwMjAyNDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences\",\"datePublished\":\"2021-05-03T10:48:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\\\/\"},\"wordCount\":497,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNzY0OCM0MTU5NzAzIzIwMjAyNDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\\\/\",\"name\":\"Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNzY0OCM0MTU5NzAzIzIwMjAyNDM=\",\"datePublished\":\"2021-05-03T10:48:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNzY0OCM0MTU5NzAzIzIwMjAyNDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNzY0OCM0MTU5NzAzIzIwMjAyNDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences - Market Newsdesk","og_description":"PLANO, Texas, May 03, 2021 (GLOBE NEWSWIRE) &#8212; Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (\u201cReata,\u201d the \u201cCompany,\u201d or \u201cwe\u201d), a clinical-stage biopharmaceutical company, today announced that management will present and hold 1&#215;1 meetings at the following investor conferences: Bank of America Merrill Lynch Global Healthcare Conference on May 12, 2021. Jefferies Virtual Healthcare Conference on June 2, 2021. About Reata Pharmaceuticals, Inc. Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata\u2019s two most advanced clinical candidates, bardoxolone methyl (&#8220;bardoxolone&#8221;) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative &hellip; Continue reading \"Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-03T10:48:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNzY0OCM0MTU5NzAzIzIwMjAyNDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences","datePublished":"2021-05-03T10:48:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/"},"wordCount":497,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNzY0OCM0MTU5NzAzIzIwMjAyNDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/","name":"Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNzY0OCM0MTU5NzAzIzIwMjAyNDM=","datePublished":"2021-05-03T10:48:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNzY0OCM0MTU5NzAzIzIwMjAyNDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNzY0OCM0MTU5NzAzIzIwMjAyNDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reata-pharmaceuticals-announces-presentations-at-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/485494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=485494"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/485494\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=485494"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=485494"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=485494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}